Cystic Fibrosis News

READ MORE

Cystic fibrosis news shared on CFRI’s social media pages related to CF research, education, advocacy, patient wellness support and more!

AUGUST, 2022

CHIESI USA ANNOUNCES THE REIMAGINED CHIESI CAREDIRECT WELLNESS PROGRAM

PFIZER, BIONTECH ASK FDA TO AUTHORIZE UPDATED BIVALENT COVID-19 VACCINE BOOSTER

POSITIVE COVID DIAGNOSIS TIED TO HIGHER HEALTHCARE UTILIZATION SIX MONTHS AFTER ILLNESS

BLOCKING PD-1 PROTEIN ACTIVATION MAY RESULT IN BETTER BACTERIA ELIMINATION

KALYDECO AT LOWER DOSAGE MAY BE AS EFFECTIVE AS HIGHER DOSE

STUDY IDENTIFIES THERAPEUTIC TARGETS FOR SEVERE COVID IN CF PATIENTS

UK APPROVES MODERNA’S BIVALENT COVID-19 VACCINE BOOSTER

NOVAVAX FILES FOR U.S. AUTHORIZATION FOR USE OF COVID-19 VACCINE AS BOOSTER

LGG SUPPLEMENT MAY EASE CF SYMPTOMS BY CHANGING GUT MICROBIOME

PHASE 1 TRIAL OF XENLETA, ANTIBIOTIC FOR MRSA INFECTIONS, FULLY ENROLLED

NEWBORN SCREENING PROGRAMS FOR CYSTIC FIBROSIS IN U.S. TIED TO IMPROVED CLINICAL OUTCOMES UP TO AGE 10 YEARS

EVIDENCE TO SUPPORT EARLY CFTR MODULATOR TREATMENT FOR CHILDREN WITH CF KEEPS GROWING

CONCERN GROWS THAT TRANSPLANT RECIPIENTS UNABLE TO ACCESS EVUSHELDFIND EVUSHELD NEAR YOU

OVER 40 PATIENT AND DISABILITY GROUPS CALL ON CONGRESS TO ENSURE DRUG PRICE NEGOTIATIONS DON’T DISCRIMINATE

PREVENTIVE DENTAL TREATMENT PRIOR TO HOSPITALIZATION TIED TO REDUCED RISK FOR NONVENTILATOR HOSPITAL-ACQUIRED PNEUMONIA

MOST ADULTS IN CF STUDY HAVE LOW BONE MINERAL DENSIT

BIOTECH COMPANY F2G DEVELOPING NEW CLASS OF ANTIFUNGAL TREATMENT

GLUCERNA, OATLY DRINKS AMONG 53 BEVERAGES RECALLED FOR POTENTIAL MICROBIAL CONTAMINATION

YARR LEADERSHIP ACADEMY APPLICATIONS ARE NOW OPEN

US CITIES, COUNTIES WEIGH REINSTATING MASK MANDATES AS COVID-19 CASES AND HOSPITALIZATIONS RISE

STUDY EXAMINES PREVALENCE OF LONG COVID IN CHILDREN

FEDERAL COURT IN TEXAS TO HEAR NEW CHALLENGE TO ACA

GLP-1 HORMONE INFUSIONS MAY BOOST INSULIN PRODUCTION IN CF PATIENTS

WNK INHIBITION INCREASES SURFACE LIQUID PH AND HOST DEFENSE IN CF AIRWAY EPITHELIA

MICHIGAN RESIDENTS: JOIN THE MICHIGAN ALL COPAYS COUNT COALITION ON SEPTEMBER 14 TO SUPPORT LEGISLATION TO HELP PATIENTS PAY FOR LIFE-SAVING MEDICATION

LUNG ALLOCATION SCORE AND OTHER PREDICTION MODELS LACK ACCURACY FOR POST-LUNG TRANSPLANT SURVIVAL

INHALED ANTIBIOTICS TIED TO GREATER RISK OF ASPERGILLUS INFECTION

 

JULY, 2022

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) LAUNCHING PHAGE THERAPY CLINICAL TRIAL

TRAVEL BENEFIT: FREE FLIGHTS FOR PATIENTS AND FAMILIES IN NEED

YARR LEADERSHIP ACADEMY APPLICATIONS ARE NOW OPEN

BA.5 OMICRON SUBVARIANT FOUR TIMES MORE RESISTANT TO COVID-19 VACCINES

PANDEMIC LED TO SURGE IN SUPERBUG INFECTIONS AND RELATED DEATHS IN US HOSPITALS

COLORADO CF COMMUNITY MEMBERS: RDAC IS BEING CREATED

GUT BACTERIA FROM ACID REFLUX MAY PROMOTE CF LUNG INFLAMMATION

MACROCYCLE MAY HELP IMPROVE CFTR FUNCTION

TRIPLE COMBINATION THERAPY FOUND TO BE SAFE AND EFFECTIVE IN CF CHILDREN HETEROZYGOUS FOR F508DEL AND A MINIMAL FUNCTION MUTATION

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) LAUNCHING PHAGE THERAPY CLINICAL TRIAL

MODERNA DEVELOPING TWO POTENTIAL OMICRON-TARGETING COVID-19 VACCINE BOOSTER SHOTS

SABIZABULIN CUT RISK OF DEATH FOR PEOPLE HOSPITALIZED WITH COVID-19 BY HALF

MODERNA VACCINE MORE LIKELY THAN PFIZER-BIONTECH TO ELICIT STRONGER RESPONSE IN IMMUNOSUPPRESSED PATIENTS

PATIENTS OF COLOR RECEIVE LESS SUPPLEMENTAL OXYGEN IN ICU THAN WHITE PATIENTS

MEASURING TISSUE STIFFNESS MAY HELP WITH DIAGNOSIS OF CF LIVER DISEASE

NOVEL METHOD DEVELOPED TO REDUCE RISK OF BACTERIAL INFECTION IN CYSTIC FIBROSIS

MS THERAPY BOOSTS TOBRAMYCIN’S EFFECTIVENESS AGAINST P. AERUGINOSA

‘VIRAL RESERVOIR’ OF SPIKE PROTEIN MAY EXPLAIN LONG-TERM COVID-19 SYMPTOMS

OMICRON-TARGETING COVID-19 VACCINE BOOSTERS TO ROLL OUT IN THE FALL

MORE FREQUENT LUNG TESTS FOUND TO IMPROVE LUNG FUNCTION IN CF YOUTH

UNC STUDY RESULT: TRIKAFTA AFTER CF LUNG TRANSPLANT NOT WELL-TOLERATED

SIGNS OF EARLY-ONSET LUNG DISEASE SEEN IN HALF OF MONITORED CF INFANTS

USE OF CFTR MODULATORS MAY PROTECT AGAINST SEVERE COVID-19

AN EXTENDED FAMILIA FOR LATINOS LIVING WITH CF

PAUSE IN IMMUNE SUPPRESSION MEDICATION SHOWN TO IMPROVE ANTIBODY RESPONSE TO COVID VACCINE

FDA ADVISERS RECOMMEND UPDATING COVID BOOSTER SHOTS FOR THE FALL

CURES 2.0 SEEKS TO SPEED DELIVERY OF TREATMENTS FOR RARE DISEASES

SENATORS LEAD BIPARTISAN EFFORT TO CURB INSULIN PRICES

STUDY HIGHLIGHTS PULMONARY EXACERBATION SUBPHENOTYPES IN CYSTIC FIBROSIS PATIENTS

PROBIOTIC VIVOMIXX MAY HELP TO RESTORE GUT MICROBIOME, EASE CFRD

CF CARRIER PREVALENCE MAY FACTOR IN VARIABILITY IN COVID-19 OUTCOMES

DOSING BEGINS IN CLINICAL TRIAL OF NEBULIZED PHAGE THERAPY FOR P. AERUGINOSA INFECTIONS

STEM CELL AGENCY JOINS CONSORTIUM DEVELOPING GENE THERAPIES FOR RARE DISEASES

CARBON BIOSCIENCES TO DEVELOP NEW VIRAL VECTOR FOR CF GENE THERAPY

ANTIBIOTIC CHANGE NOT SEEN TO IMPROVE LUNG FUNCTION AFTER FLARE

EARLY TREATMENT WITH AZITHROMYCIN HAS SOME BENEFITS FOR CF INFANTS

COVID-19 POSES GREATER DANGER TO CHILDREN THAN SEASONAL FLU

 

JUNE, 2022

VIRUSES RARELY SEEN DURING THE PANDEMIC ARE SPREADING AGAIN

COVID-19 ANTIBODIES MAY PERSIST NEARLY 500 DAYS AFTER INFECTION

FDA ADVISORY COMMITTEE SUPPORTS AUTHORIZATION OF NOVAVAX’S COVID-19 VACCINE

FTC LAUNCHES INQUIRY INTO PRESCRIPTION DRUG MIDDLEMEN INDUSTRY

PP-007 RESOLVES LUNG INFLAMMATION IN CF MOUSE MODEL

FUNDING AWARDED FOR RESEARCH INTO AMINOGLYCOSIDES AND HEARING LOSS

HOW DANGEROUS IS MONKEYPOX?

DATA SHOW SEVEN-DAY AVERAGE OF COVID-19 CASES IS SIX TIMES HIGHER THAN LAST YEAR AT THIS TIME

CDC RECOMMENDS RE-ISOLATION IF COVID RECURS AFTER TREATMENT WITH PAXLOVID

ETHNIC MINORITIES LESS LIKELY TO BE ELIGIBLE FOR TRIPLE COMBINATION CFTR MODIFIER

BREATH BIOMARKERS SHOW POTENTIAL FOR IDENTIFYING NTM LUNG INFECTIONS

$2.7M NIH GRANT SUPPORTS WORK INTO STEM CELL ROLE IN LUNG INFLAMMATION

MAY, 2022

BACTERIOPHAGES ELIMINATE TREATMENT-RESISTANT M. ABSCESSUS LUNG INFECTION

PFIZER, BIONTECH SUBMIT APPLICATION FOR EMERGENCY USE AUTHORIZATION OF COVID-19 BOOSTER SHOT FOR CHILDREN

NEARLY 60% OF U.S. POPULATION HAS HAD CORONAVIRUS INFECTION

ABBVIE HALTS DEVELOPMENT OF ABBV-119 CORRECTOR, WILL CONTINUE WORKING TOWARDS TRIPLE COMBINATION

LUNG CLEARANCE INDEX ABLE TO IDENTIFY CHILDREN WITH CF AT RISK OF EXACERBATIONS

LUNG-PANCREATIC CELL TRANSPLANT SAFE, EFFECTIVE IN CF PATIENTS WITH CFRD

FEDERAL ADMINISTRATION TO PROMOTE SUPPLY OF AND IMPROVE ACCESS TO PAXLOVID

CDC RECOMMENDS MOST AMERICANS UNDER 50 SHOULD WAIT FOR NEXT GENERATION OF COVID-19 VACCINE BOOSTERS

FDA GRANTS FULL APPROVAL TO REMDESIVIR FOR TREATMENT OF COVID-19 IN CHILDREN

SALIVA OF ADULTS WITH CF CONTAINS ANTI-INFLAMMATORY FATTY MOLECULES

NANOPARTICLES IMPROVE DRUG DELIVERY FOR LUNG DISEASES

COMMON ENVIRONMENTAL FUNGUS CAN WORSEN LUNG FUNCTION IN CHILDREN WITH CF

APRIL, 2022

RISK OF BREAKTHROUGH INFECTIONS TIED TO PSYCHIATRIC PROBLEMS

SEVERAL RISK FACTORS TIED TO DIMINISHED ANTIBODY RESPONSE TO COVID-19 VACCINATION IN ORGAN TRANSPLANT RECIPIENTS

INHALED HYPERTONIC SALINE TIED TO BENEFICIAL LUNG CHANGES IN YOUNG CHILDREN WITH CF

SIONNA THERAPEUTICS RECEIVES FUNDING FROM ORBIMED AND THE CF FOUNDATION FOR MODULATOR DEVELOPMENT

FIRST PATIENT ENROLLED IN PHASE 1 TRIAL TESTING ANTIBIOTIC XENLETA FOR CF

ATS PAR PATIENTS & EXPERTS FORUM – IMPROVING LUNG HEALTH: WHAT’S ON THE HORIZON

FDA GRANTS EMERGENCY USE AUTHORIZATION TO COVID-19 BREATHALYZER TEST

CDC ASKS JUSTICE DEPARTMENT TO APPEAL TRANSPOPRTATION MASK RULING

NONINVASIVE ELASTOGRAPHY PREDICTS LIVER SCARRING SEVERITY IN CHILDREN

FIRST PATIENT DOSED IN TRIAL OF AEROSOL-DELIVERED GENETIC MEDICINE

COLORADO RARE DISEASE ADVISORY COUNCIL LEGISLATION INTRODUCED

OREGON SEEKS TO LIMIT MEDICAID COVERAGE OF ACCELERATED-APPROVAL DRUGS

CALL FOR CF PATIENT NOMINATIONS: WHAT’S YOUR GAP?

MEDICARE BEGINS COVERING AT-HOME COVID-19 TESTS FOR PART B BENEFICIARIES

OMICRON SUBVARIANT BA.2 ACCOUNTS FOR 72.2% OF COVID-19 VARIANTS IN US, CDC ESTIMATES

EXPRESSION OF ACE2 – A KEY SARS-COV-2 ENTRY FACTOR – IS NOT INCREASED IN THE NASAL MUCUS OF PEOPLE WITH CF

CYSTIC FIBROSIS CARRIERS ARE AT INCREASED RISK FOR A WIDE RANGE OF CF-RELATED CONDITIONS

KIT2014 INCREASED CFTR MODULATOR EFFICACY IN PRECLINICAL STUDY

MANY UNINSURED LOSE ACCESS TO FREE COVID-19 TESTING, TREATMENT, AND VACCINES

FDA AUTHORIZES SECOND BOOSTER SHOTS FOR ADULTS AGED 50 AND OLDER

MAINE RDAC EFFORTS: CFRI JOINS 14 PATIENT ADVOCACY GROUPS SUPPORTING CREATION OF RARE DISEASE ADVISORY COUNCIL

ANTIBIOTICS LESS EFFECTIVE AGAINST MIX OF MICROBES IN LUNG INFECTION

METABOLITES ASSOCIATED WITH LOWER AIRWAY INFECTION AND INFLAMMATION

AB 1880 INTRODUCED TO CA ASSEMBLY COMMITEE ON HEALTH.

MARCH, 2022

TOP-RATED CHARITIES TO HELP THE UKRAINE RELIEF EFFORT

DIABETES SISTERS PROVIDE OVERVIEW OF INSULIN OPTIONS

DRUG COMPANIES REACH DEAL TO PRODUCE LOW-COST VERSIONS OF PFIZER’S COVID-19 DRUG

MODERNA ASKS FDA TO AUTHORIZE SECOND COVID-19 BOOSTER DOSE FOR ALL ADULTS

HIGH LEVELS OF DMBT1 PROTEIN IN LUNGS MAY MARK CF PROGRESSION

CLINICAL OUTCOMES OF ANTIPSEUDOMONAL VERSUS OTHER ANTIBIOTICS AMONG CHILDREN WITH CF WITHOUT PSEUDOMONAS AERUGINOSA

BACTERIA BOOSTS ANTI-FUNGAL MEDICINE’S KILLING POWER IN CF STUDY

CANADIAN RESEARCHERS TO STUDY NEW CELL TYPES IN CF

LIPID-DRIVEN CFTR CLUSTERING IS IMPAIRED IN CF AND RESTORED BY TRIKAFTA

HOW TO DEAL WITH AN INSURANCE DENIAL – FACT SHEET AVAILABLE

GUNNAR ESIASON OP-ED SHEDS LIGHT ON DANGERS OF FLAWED HEALTH TECHNOLOGY ASSESSMENTS

REINFECTIONS WITH OMICRON CORONAVIRUS SUBVARIANTS POSSIBLE BUT RARE

FULLY VACCINATED PEOPLE LESS LIKELY TO SUFFER FROM LONG COVID

IVERMECTIN DOES NOT PREVENT PATIENTS WITH COVID-19 FROM BECOMING SEVERELY ILL

CLINICAL EFFECTIVENESS OF ELEXACAFTOR/ TEZACAFTOR/IVACAFTOR IN PEOPLE WITH CF

HOW TO DEAL WITH AN INSURANCE DENIAL – FACT SHEET AVAILABLE

FDA WARNS AGAINST THREE UNAUTHORIZED COVID-19 TESTS OVER CONCERNS OF FALSE RESULTS

COVID-19 PATIENTS IN HIGH-VULNERABILITY ZIP CODES AT GREATER RISK FOR WORSE HEALTH OUTCOMES

HEALTH CANADA CLEARS MEDICAGO’S PLANT-BASED COVID-19 VACCINE FOR USE IN ADULTS

RESULTS FROM SURVEY OF PEOPLE WITH CF INELIGIBLE TO TAKE CFTR MODULATORS

KROGER COMMUNITY REWARDS PROGRAM: SIGN UP TO SUPPORT CFRI

LUNG FUNCTION OF CHILDREN WITH CYSTIC FIBROSIS DIFFERENT IN US VS UK

A SINGLE-CELL ATLAS OF LARGE AND SMALL AIRWAYS AT BIRTH IN A PORCINE MODEL OF CF

TRIKAFTA LEADS TO REDUCED NEED FOR ANTIBIOTICS, FEWER HOSPITALIZATIONS

EUROPEAN CYSTIC FIBROSIS ORGANIZATIONS UNITE TO RAISE FUNDS FOR UKRAINIANS WITH CF

RARE DISEASE ADVISORY COUNCILS EXPLAINED IN TWO MINUTES

CFRI CO-SIGNS LETTER IN SUPPORT OF MD HB 1015

HELP COPAYS ACT SEEKS TO FIGHT HIGH OUT-OF-POCKET INSURANCE COSTS

COVID ANTIBODY DRUG EVUSHELD OFTEN GOES UNUSED

EVEN MILD CASES OF COVID CAN CAUSE BRAIN DAMAGE AND SHRINKAGE

FEBRUARY, 2022

ACHROMOBACTER INFECTION IN CHILDREN LINKED TO WORSE LUNG FUNCTION

PARTIAL MONOCYTE TRANSPLANT IMPROVES SURVIVAL IN MOUSE STUDY

ADMINISTRATION TO PROVIDE AMERICANS WITH 400M FREE N95 MASKS

ANTIBODIES CAPABLE OF BLOCKING OMICRON VARIANT PERSIST FOUR MONTHS AFTER PFIZER-BIONTECH BOOSTER SHOT

FDA HALTS USE OF TWO COVID-19 MONOCLONAL ANTIBODY THERAPIES

PFIZER BEGINS TESTING OMICRON-SPECIFIC COVID VACCINE IN ADULTS

CFRI CO-SIGNS LETTER BY ALL COPAYS COUNT COALITION TO HHS REGARDING CO-PAY ACCUMULATORS

BODY MASS INDEX RECOVERY FOLLOWING LUNG TRANSPLANT FOR CYSTIC FIBROSIS

EXON-SKIPPING MOLECULES SHOW POTENTIAL TO TREAT NONSENSE MUTATIONS IN CF

KAFTRIO RESCUES CHLORIDE, BICARBONATE DEFICITS IN GI TISSUES\

FDA GRANTS FULL APPROVAL TO MODERNA’S COVID-19 VACCINE

PFIZER AND BIONTECH SEEK FDA EMERGENCY USE AUTHORIZATION FOR COVID-19 VACCINE FOR CHILDREN YOUNGER THAN 5

NEW ONLINE RESOURCE TO TRACK USE OF QALY ACROSS STATES

LATEST AIDS INSTITUTE REPORT ON COPAY ACCUMULATOR POLICIES SHOWS DISCRIMINATION AGAINST PATIENTS WITH CHRONIC ILLNESSES

SELF-SCREENING TOOL DEVELOPED FOR NONWHITE CF POPULATIONS

OVER HALF OF CHILDREN WITH CF SHOW POOR CARDIORESPIRATORY FITNESS IN STUDY

PERSONALIZED MEDICINES FOR RARE MUTATIONS FOCUS OF EU PROJECT

HEALTH INSURERS BEGIN CHARGING PATIENTS FOR COVID-19 CARE

COVID-19 AEROSOL PARTICLES FOUND BOTH INSIDE AND OUTSIDE OF ROOMS OF PEOPLE SELF-ISOLATING AT HOME

POTENTIAL RISK OF STRANGULATION IN CHILDREN WHO USE ENTERAL FEEDING DELIVERY SETS

JANUARY, 2022

MOLECULE SHOWS EARLY POTENTIAL IN TREATING CF DUE TO F508DEL MUTATION

SINUS SURGERY MOST SUCCESSFUL IF PERFORMED WITHIN FIRST YEARS AFTER LUNG TRANSPLANT

TRIKAFTA MAY IMPROVE VITAMIN D ABSORPTION IN CF PATIENTS

FDA WARNS ANTIGEN TESTS MAY BE LESS EFFECTIVE IN DETECTING OMICRON VARIANT

PLATFORMS OF HOPE: ADVANCES IN GENE THERAPY & GENE EDITING

ENBIOTIX RAISES $11M TO DEVELOP ANTIBIOTICS FOR LUNG INFECTIONS

IRON BUILDUP MAY LEAD TO DEATH OF CF AIRWAY CELLS

BIOMX RECEIVES GRANT FOR PHASE 1/2 TRIAL OF PHAGE THERAPY FOR P. AERUGINOSA INFECTIONS

STUDY SHOWS POSITIVE IMPACT OF CFTR MODULATORS ON ABILITY TO FEND OFF SEVERE COVID-19

COVID-19 HOSPITALIZATIONS AMONG CHILDREN AT RECORD NUMBERS AMID OMICRON SURGE

FDA AUTHORIZES COVID-19 VACCINE BOOSTERS FOR CHILDREN 12-15 YEARS

CREATIVE EFFORT TO ENCOURAGE VACCINATIONS: 700 SHEEP AND GOATS ARRANGED IN THE SHAPE OF A SYRINGE

BIOBONDS LEGISLATION FEATURED IN OP-ED

PEPTILOGICS RECEIVES GRANT TO RESEARCH THERAPIES TO FIGHT LUNG BACTERIA

SPL84-23 FOR CF SPLICING MUTATION NAMED ORPHAN DRUG IN U.S. AND EUROPE

GRANT AWARDED TO SUPPORT RESEARCH FOR TREATMENT OF CHRONIC RHINOSINUSITIS

EVERY VACCINATED PARTICIPANT WITH SERIOUS COVID-19 OUTCOMES HAD AT LEAST ONE RISK FACTOR

STUDY RAISES DOUBTS OVER EFFECTIVENESS OF RAPID AT-HOME COVID-19 ANTIGEN TESTS TO DETECT OMICRON VARIANT

LATEST DATA ON COVID-19 VACCINATIONS BY RACE AND ETHNICITY

HIGH LEVELS OF T CELLS FROM COMMON COLD MAY HELP PREVENT COVID-19

FEDERAL WEB SITE FOR AMERICANS TO REQUEST FREE COVID-19 TESTS LAUNCHED

NEW CAPSULE FORM OF ADRULIPASE ALFA FOR EPI MAY SOON ENTER TRIAL

FELDAN THERAPEUTICS RECEIVES FUNDING TO DEVELOP TECHNOLOGY TO IMPROVE MEDICINE DELIVERY

TRIKAFTA RESCUES CFTR AND LOWERS MONOCYTE P2X7R-INDUCED INFLAMMASOME ACTIVATION IN CF

CLOTH MASKS NOT AS EFFECTIVE AS SURGICAL MASKS, RESPIRATORS AGAINST COVID-19

DECEMBER, 2021

7 MILLION UNINSURED PEOPLE ARE ELIGIBLE FOR MEDICAID OR CHIP

OVERUSE OF ANTIBIOTICS DURING PANDEMIC FUELING DRUG-RESISTANT INFECTIONS

NATIONAL COUNCIL ON DISABILITIES PROVIDES RECOMMENDATIONS TO STRENGTHEN PROTECTIONS FOR PATIENTS AND INDIVIDUALS WITH DISABILITIES UNDER BBBA

PFIZER AND BIONTECH SAY THEIR COVID-19 VACCINE IS 100% EFFECTIVE IN ADOLESCENTS AGED 12 TO 15 YEARS

LUNG AIRWAY CHIP ACCURATELY MODELS CYSTIC FIBROSIS

TRIKAFTA INCREASES MICROBIOME DIVERSITY IN LUNGS

CREATION OF BILE DUCT CELLS MAY HELP TREAT CF LIVER DISEASE

FDA PANEL SUPPORTS EMERGENCY USE OF MERCK COVID DRUG

NEW AND POTENTIALLY MORE TRANSMISSIBLE CORONAVIRUS VARIANT CAUSES CONCERN

LUNG TRANSPLANTS FOR COVID-19 PATIENTS ARE RISING QUICKLY

OPINION: HOW HEALTH CARE SYSTEMS DO, AND DO NOT, SUPPORT PATIENTS

NEW ATS DOCUSERIES ON RESPIRATORY HEALTH

FDA AUTHORIZES NEW MONOCLONAL ANTIBODIES FOR PREVENTION OF COVID-19 IN CERTAIN INDIVIDUALS

FDA AUTHORIZES ELI LILLY’S COVID-19 MONOCLONAL ANTIBODY TREATMENT FOR YOUNG, AT-RISK CHILDREN

NASAL EPITHELIAL CELLS GROWN IN CULTURE SHOW POTENTIAL TO BE USED IN CF STUDIES

FULL CFTR GENE ANALYSIS IDENTIFIES MUTATIONS THAT ARE MISSED IN STANDARD TESTING

SELF-COMPASSION TIED TO BETTER QUALITY OF LIFE IN ADULTS WITH CF

OMICRON VARIANT APPEARS TO SHARE GENETIC CODE WITH COMMON COLD CORONAVIRUS, MAY HAVE GREATER TRANSMISSIBILITY

FIRST DOSE OF ASTRAZENECA-OXFORD OR PFIZER-BIONTECH COVID-19 VACCINES OFFERS BETTER IMMUNE RESPONSE WHEN FOLLOWED BY MODERNA SHOT

PULMOCIDE RECEIVES GRANT TO SUPPORT WORK ON ANTIFUNGAL THERAPY FOR LUNG TRANSPLANTS

BLOCKING PROTEIN OF GLUCOSE UPTAKE, SGLT1, MAY HELP IN TREATING CF

MANY WOMEN WITH CF LACK INFORMATION ON FERTILITY PRESERVATION

OMICRON VARIANT: LESS SEVERE ILLNESS, MORE RESISTANT TO PFIZER-BIONTECH COVID-19 VACCINE

PFIZER SAYS ITS ANTIVIRAL COVID-19 PILL IS NEARLY 90% EFFECTIVE IN FINAL ANALYSIS

1.1M DEATHS, 10.3M HOSPITALIZATIONS PREVENTED DURING FIRST YEAR OF US COVID-19 VACCINE PROGRAM

THE “NO SURPRISES ACT” WILL TAKE EFFECT IN JANUARY 2022

LIFE EXPECTANCY FOR CHILDREN WITH CF IN THE UK SURPASSES 50 FOR THE FIRST TIME

TRIKAFTA MAY BE SAFE AND EFFECTIVE FOR LIVER TRANSPLANT PATIENTS

P. AERUGINOSA BACTERIUM ADAPTS OVER TIME TO BECOME MORE RESISTANT

FDA AUTHORIZES FIRST ORAL ANTIVIRAL FOR TREATMENT OF COVID-19

OMICRON IS NOW THE DOMINANT CORONAVIRUS STRAIN IN THE UNITED STATES

MODERNA SAYS COVID BOOSTER APPEARS TO PROTECT AGAINST OMICRON

NOVEMBER, 2021

PHAGE THERAPY CLINICAL TRIAL RECRUITING PARTICIPANTS

LUNGFIT GO FOUND TO BE SAFE AND WELL-TOLERATED IN INTERIM TRIAL DATA

BOEHRINGER ACQUIRES RIGHTS TO POTENTIAL CF INHALATION GENE THERAPY

FDA ADVISERS VOTE TO RECOMMEND COVID-19 VACCINES FOR CHILDREN 5 TO 11

SOUTH AFRICAN RESEARCHERS WORKING TO REPLICATE MODERNA COVID-19 VACCINE TO COM-BAT VACCINE DISPARITIES

HEALTH DISPARITY IN CF: PERSPECTIVES FROM A LIVED EXPERIENCE

DIFFERENCES IN BACTERIAL COMMUNITIES AND INFLAMMATION IN LOWER AIRWAYS ARE EVIDENT BY AGE TWO

ARMATA PHARMACEUTICALS RECEIVES $3M FOR DEVELOPMENT OF PHAGE THERAPY

INCREASE IN PATIENT ADHERENCE TO THERAPY WITH GUIDED PLATFORM

CDC APPROVES PFIZER-BIONTECH COVID-19 VACCINE FOR YOUNGER CHILDREN

VACCINATION PROVIDES STRONGER, MORE RELIABLE PROTECTION AGAINST CORONAVIRUS THAN PAST INFECTION

OVER 230 NATIONAL ORGANIZATIONS URGE GOVERNORS ACROSS THE COUNTRY TO PROTECT PATIENTS’ ACCESS TO TELEHEALTH

ACERAGEN ACQUIRES POTENTIAL ORAL ANTIBIOTIC FOR CF PULMONARY FLARES

TRIKAFTA MAY BENEFIT SOME LUNG TRANSPLANT RECIPIENTS

GENE THERAPY SP-101 SHOWS POTENTIAL IN ANIMAL STUDY

PFIZER’S ANTIVIRAL PILL EFFECTIVE AGAINST COVID-19

RESEARCHERS IDENTIFY GENE THAT DOUBLES RISK OF RESPIRATORY FAILURE FROM COVID-19

GETTING TELEHEALTH POLICY RIGHT: A NATIONAL SUMMIT: READ SUMMARY | WATCH RECORDING

OVER 230 NATIONAL ORGANIZATIONS URGE GOVERNORS ACROSS THE COUNTRY TO PROTECT PATIENTS’ ACCESS TO TELEHEALTH

ELEXACAFTOR ALSO WORKS AS CFTR POTENTIATOR

BRONCHITOL–PULMOZYME COMBINATION EFFECTIVE IN CLEARING KIDS’ LUNGS

KIDS NASAL SWAB TESTS CONDUCTED BY PARENTS YIELD ACCURATE RESULTS

VIATRIS AND BIOCON BIOLOGICS ANNOUNCE LAUNCH OF INTERCHANGEABLE SEMGLEE®

COVID-19 CASES IN US ARE UP NEARLY 27% IN LAST THREE WEEKS, CDC SAYS

ELX-02 LOWERS SWEAT CHLORIDE IN PATIENTS WITH G542X MUTATION

P. AERUGINOSA METABOLITES MAY ENABLE BETTER THERAPEUTIC MANAGEMENT

HYPERTONIC SALINE FOUND TO BE EFFECTIVE AND SAFE FOR YOUNG CHILDREN WITH CF

OCTOBER, 2021

TRIKAFTA NOW COVERED IN 2 MORE CANADIAN PROVINCES

ANTIBIOTIC-RESISTANT BACTERIA IN FISH TREATED BY ADDING PHAGE THERAPY

ULTRASOUNDS MAY HELP DIAGNOSE PANCREATIC INSUFFICIENCY IN CHILDREN WITH CF

TWO STUDIES PROVIDE EVIDENCE THAT MASKS PROTECT CHILDREN FROM CORONAVIRUS – Study 1Study 2

COVID-19 VACCINES DO NOT INCREASE RISK OF MISCARRIAGE OR BIRTH DEFECTS

NIH DIRECTOR DR. FRANCIS COLLINS STEPPING DOWN

CF PATIENTS WITH COVID-19 AT HIGHER RISK OF POOR OUTCOMES

PHASE 1 STUDY OF KB407 TO BE LAUNCHED IN AUSTRALIA

CDC RELEASES GUIDANCE FOR UPCOMING HOLIDAY SEASON

FDA ISSUES BEST PRACTICES FOR COMMUNICATING CYBERSECURITY VULNERABILITIES TO PATIENTS

CDC RECOMMENDS COVID BOOSTER SHOT FOR ALL ADULTS

PFIZER AND BIONTECH SAY THEIR COVID-19 VACCINE IS 100% EFFECTIVE IN ADOLESCENTS AGED 12 TO 15 YEARS

OVERUSE OF ANTIBIOTICS DURING PANDEMIC FUELING DRUG-RESISTANT INFECTIONS

NATIONAL COUNCIL ON DISABILITIES PROVIDES RECOMMENDATIONS TO STRENGTHEN PROTECTIONS FOR PATIENTS AND INDIVIDUALS WITH DISABILITIES UNDER BBBA

NEW ATS DOCUSERIES ON RESPIRATORY HEALTH

7 MILLION UNINSURED PEOPLE ARE ELIGIBLE FOR MEDICAID OR CHIP

INHALATION POWDER FOR MUCUS CLEARANCE AVAILABLE FOR THOSE WHO PASS THE BRONCHITOL TOLERANCE TEST

PHASE 1/2 TRIAL OF AEROSOL GENE THERAPY FOR CF MAY START SOON

GUT MICROBIOME SLOW TO DEVELOP IN CF INFANTS

EPICORE LAUNCHES WEARABLE PATCH TO CONDUCT SWEAT COLLECTION TESTS

PFIZER, BIONTECH ASK FDA TO AUTHORIZE CORONAVIRUS VACCINE FOR CHILDREN 5 TO 11 YEARS OLD

MERCK APPLIES FOR FDA EMERGENCY AUTHORIZATION FOR ANTIVIRAL PILL TO TREAT COVID-19

MOST MAC LUNG INFECTIONS LIKELY NOT PASSED FROM PATIENT TO PATIENT

LIVER DISEASE IN CF APPEARS LINKED TO PROBLEMS IN CFTR PROTEIN

ANIMAL CELL CULTURE-DEVELOPED FLU VACCINE EFFECTIVE IN CHILDREN

FDA PANEL BACKS BOOSTER DOSE FOR ALL J&J COVID-19 VACCINE RECIPIENTS

ANXIETY DUE TO COVID-19 LOWER IN CHILDREN WITH CF THAN THEIR PEERS

FDA PANEL RECOMMENDS MODERNA CORONAVIRUS BOOSTER FOR PEOPLE 65 YEARS AND OLDER, ADULTS AT HIGH RISK

SEPTEMBER, 2021

MS1819 PLUS PERT IMPROVED FAT ABSORPTION IN SEVERE EPI

CONTRIBUTE YOUR PERSONAL EXPERIENCES WITH TRIKAFTA TO CF RESEARCH

HEALTH DISPARITY IN CF: PERSPECTIVES FROM A LIVED EXPERIENCE

CENTERS FOR MEDICARE AND MEDICAID SERVICES ISSUE NEW CODE FOR ENCALA

PFIZER-BIONTECH’S COVID VACCINE RECEIVES FULL FDA APPROVAL

MONOCLONAL ANTIBODY TREATMENT HIGHLY EFFECTIVE AGAINST MILD TO MODERATE COVID-19

WORLD HEALTH ORGANZIATION CALLS FOR TWO-MONTH VACCINE BOOSTER MORATORIUM

LUNG CLEARANCE INDEX USEFUL IN ASSESSING LUNG FUNCTION

KALYDECO APPROVED IN CANADA TO TREAT INFANTS 4 MONTHS AND OLDER

FDA UNDER GROWING PRESSURE TO AUTHORIZE COVID-19 VACCINES FOR CHILDREN YOUNGER THAN 12

EXPERTS WORRY CHILDREN OF COLOR FACE GREATEST RISK AS COVID-19 INFECTS MORE CHILDREN IN US

PRIOR COVID-19 INFECTION MAY NOT GUARANTEE HIGH LEVEL OF ANTIBODIES OR STRONG RESPONSE AFTER JUST ONE COVID-19 VACCINE DOSE

CHOOSING AN AIR PURIFIER TO ADDRESS COVID AND WILDFIRE SMOKE

POLYPHOR AND ENBIOTIX TO MERGE, PLAN TRIALS IN 2 LUNG INFECTION THERAPIES

MINORITIES WITH CF MORE LIKELY TO EXPERIENCE LOWER LUNG FUNCTION THAN CAUCASIAN PATIENTS

PEDIATRIC HOSPITALIZATIONS DUE TO COVID-19 SPIKED DURING SUMMER MONTHS AMID DELTA VARIANT SPREAD

WHO MONITORING NEW CORONAVIRUS “VARIANT OF INTEREST.”

NORTH CAROLINA CO-PAY ACCUMULATOR BAN PASSES AND AWAITS GOVERNOR’S SIGNATURE

HHS PROPOSES TO WITHDRAW DRUG PRICING RULE

AVERAGE COVID-19 HOSPITALIZATION COSTS MEDICARE 150 TIMES MORE THAN VACCINATING ONE INDIVIDUAL, ANALYSIS SHOWS

BIDEN ADMINISTRATION ANNOUNCES COVID-19 VACCINE MANDATE FOR FEDERAL WORKERS, CONTRACTORS, PRIVATE COMPANIES WITH MORE THAN 100 WORKERS

MORE AMERICANS HAD COVID-19 AT THE END OF 2020 THAN PREVIOUSLY ESTIMATED

ELX-02, POTENTIAL CF NONSENSE MUTATION THERAPY, ON FDA FAST TRACK

SFPQ PROTEIN HELPS TO RESTORE CFTR IN CELLS WITH COMMON MUTATION

STUDY SHOWS VALUE OF BIOFILM COMPONENT IN P. AERUGINOSARESISTANCE

FDA SAYS IT HOPES TO MOVE QUICKLY ON AUTHORIZING COVID-19 VACCINES FOR YOUNGER CHILDREN

THE FIGHT FOR A LIFE-CHANGING DRUG: GETTING TRIKAFTA APPROVED IN ALBERTA

PANDEMIC PLACES SOCIOECONOMIC HARDSHIPS ON CF PATIENTS

PUBLIC REIMBURSEMENT OF TRIKAFTA ONE STEP CLOSER IN CANADA

AIRPHYSIO LUNG CLEARANCE DEVICE NOW SOLD ONLINE FOR U.S. PATIENTS

JOHNSON & JOHNSON’S COVID-19 VACCINE IS MORE EFFECTIVE WHEN GIVEN AS A TWO-DOSE REGIMEN

ONE IN THREE PEOPLE WHO SURVIVED COVID-19 REPORT SUFFERING FROM LONG COVID

EMILY’S ENTOURAGE HOSTED FDA LISTENING SESSION FOR THE FINAL 10% OF PEOPLE WITH CYSTIC FIBROSIS

FTC ISSUES STATEMENT CONFIRMING CONNECTED DEVICES MUST COMPLY WITH DATA BREACH RULE

 

AUGUST, 2021

SECRETORY CELLS DOMINATE AIRWAY CFTR EXPRESSION AND FUNCTION IN HUMAN AIRWAY SUPERFICIAL EPITHELIA

SEMGLEE APPROVED AS FIRST INTERCHANGEABLE BIOSIMILAR INSULIN PRODUCT

INDIVIDUALS WITH CYSTIC FIBROSIS DO NOT APPEAR TO HAVE HIGHER RISK FOR SARS-COV-2 INFECTION

NUTRITIONAL STATUS OF CHILDREN WITH CF LINKED TO TEENAGE-ONSET DIABETES

SANOFI TO ACQURE TRANSLATE BIO

CDC SUGGESTS VACCINATED INDIVIDUALS INFECTED WITH DELTA CORONAVIRUS VARIANT CARRY HIGH VIRAL LOADS

CDC CALLS FOR FULLY VACCINATED INDIVIDUALS TO BE TESTED FOR COVID-19 FOLLOWING EXPOSURE EVEN IF ASYMPTOMATIC

IT IS TIME TO LET GO OF THE QALY”S LEGACY OF DISCRIMINATION

LOW BONE DENSITY IN CF ADULTS MAY BE TIED TO INFLAMMATION MARKER

CFTR PROTEIN DYNAMIC, CHANGING SHAPES IN WAYS AFFECTING DISEASE

CHRONIC SINUS INFLAMMATION MAY ALTER BRAIN ACTIVITY

BIONTECH SAYS BOOSTER SHOT A BETTER STRATEGY THAN TAILORING VACCINE TO NEW VARIANT

US TOPS 100,000 DAILY COVID-19 CASES FOR FIRST TIME SINCE WINTER

STUDY SHOWS J&J COVID-19 VACCINE 96.2% EFFECTIVE AGAINST SEVERE ILLNESS AND DEATH

HHS PROPOSES TO WITHDRAW DRUG PRICING RULE

INSURERS OPPOSE HHS PROPOSAL TO EXTEND ACA ANNUAL ENROLLMENT PERIOD

COLLEGE STUDENT WITH CF APPOINTED TO NEW RARE DISEASE ADVISORY COUNCIL IN OHIO

ATS/AMERICAN LUNG ASSOC. JOINT STATEMENT OPPOSING PHILLIP MORRIS INT’L BID TO AQUIRE VECTURA

PATIENT GROUPS AMENDMENTS TO CALIFORNIA AB 1130

PRIME EDITING, ADVANCE ON CRISPR, SHOWS POTENTIAL ON CFTR MUTATIONS

NEW METHOD TO PRODUCE HIGH-YIELD, HIGH-PURITY RNA MAY AID CF TREATMENT

LUNG TRANSPLANT BIOREPOSITORY, REGISTRY TARGETS PATIENT OUTCOMES

BOOSTER DOSE OF COVID VACCINE NOW RECOMMENDED FOR THE IMMUNO-COMPROMISED

MULTIPLE SAFETY MEASURES CAN PROVIDE STRONG PROTECTION AGAINST COVID-19 AMID RETURN TO IN-PERSON LEARNING

CALIFORNIA SENATE BILL 247 TO BE HEARD IN ASSEMBLY APPROPRIATIONS COMMITTEE AUGUST 19

LETTER IN OPPOSITION TO PMI ACQUISITION OF VECTURA

INSURERS OPPOSE HHS PROPOSAL TO EXTEND ACA ANNUAL ENROLLMENT PERIOD

BABIES AND TODDLERS SPREAD VIRUS IN HOMES MORE EASILY THAN TEENS, STUDY FINDS

RACIAL, SOCIAL DISPARITIES INFLUENCE ASTHMA-RELATED HOSPITAL READMISSIONS

 

JULY, 2021

MORNINGS ARE TOUGH WITH CF

THE WHO SAYS FULLY VACCINATED PEOPLE SHOULD CONTINUE TO WEAR FACE MASKS IN PUBLIC SETTINGS

LOW LEVELS OF VIP HORMONE MAY CONTRIBUTE TO EARLY CF-RELATED DIABETES

SEVERE COVID-19 MORE LIKELY IN CF CARRIERS THAN PATIENTS

JOINT DISEASE LINKED TO P. AERUGINOSA INFECTION, FEMALE SEX

SOME MINORS SEEK TO GET COVID-19 VACCINE AGAINST PARENTS’ WISHES

STUDY SUGGESTS MODERNA COVID-19 VACCINE EFFECTIVE AGAINST DELTA VARIANT

DELTA VARIANT IS MAKING OFFICIALS RETHINK MASK GUIDELINES

WHO ESTIMATES YEARLY COVID-19 BOOSTERS MAY BE NEEDED FOR MOST VULNERABLE

SUPREME COURT REJECTS LATEST CHALLENGE TO AFFORDABLE CARE ACT

TENSIN 1 GENE VARIANTS MAY AFFECT NUTRITION IN CF PATIENTS

ARROWHEAD PAUSES ARO-ENAC STUDY AMID SAFETY CONCERNS

11% OF PEOPLE IN THE U.S. HAVE MISSED THEIR SECOND COVID-19 VACCINE DOSE

US HEALTH OFFICIALS NOT YET RECOMMENDING THIRD DOSE OF COVID-19 VACCINE FOR PEOPLE WITH IMMUNE CONDITIONS

AIRWAY INFLAMMATION AFFECTS PH, RESPONSE TO CFTR THERAPIES

DATA FROM PHASE 2 TRIALS OF ELX-02 EXPECTED THIS YEAR

UNDERVACCINATED CLUSTERS MAY BECOME BREEDING GROUNDS FOR MORE FATAL CORONAVIRUS VARIANTS

PFIZER-BIONTECH TO SEEK FDA AUTHORIZATION FOR THIRD DOSE OF COVID-19 VACCINE

FDA CLEARS TACROLIMUS TO PREVENT LUNG TRANSPLANT REJECTION

HORMONE FLUCTUATIONS TIED TO CHANGES IN LUNG FUNCTION IN WOMEN WITH CYSTIC FIBROSIS

STUDY DESCRIBES NEW COMPOUND FOR NONSENSE MUTATIONS

FDA GRANTS PRIORITY REVIEW TO PFIZER-BIONTECH’S APPLICATION FOR FULL APPROVAL OF COVID-19 VACCINE

WILDFIRE SMOKE MAY INCREASE RISK OF COVID-19

 

JUNE, 2021

RACE, INCOME LIMIT CF LUNG TRANSPLANT ACCESS IN US MORE THAN CANADA

ELOXX ANNOUNCES FUNDING AWARD FROM CFF FOR DEVELOPMENT OF RIBOSOME MODULATING AGENTS (RMAs)

TRIKAFTA RECEIVES FDA APPROVAL FOR USE IN CHILDREN WITH CYSTIC FIBROSIS, AGE 6-11 WITH CERTAIN MUTATIONS

BENEFITS OF TRIPLE-COMBO TRIKAFTA FOR CF MOSTLY DUE TO ELEXACAFTOR

NEW CELL RESEARCH MODEL SHOWS PROMISE AGAINST P. AERUGINOSA

DR. FAUCI URGES VACCINATION AGAINST COVID-19 VARIANT SPREADING TO US FROM INDIA

UNITEDHEALTHCARE DELAYS PLANS TO DENY SOME EMERGENCY VISITS AMID OUTCRY

ANTIBODY-LADEN NASAL SPRAY COULD PROVIDE COVID PROTECTION

PHILIPS RECALLS MILLIONS OF VENTILATORS, SLEEP APNEA DEVICES OVER POTENTIAL HEALTH RISKS

RNA-BASED THERAPIES SHOW PROMISE IN EARLY STUDIES

MOLECULES IN PATIENTS’ BREATH MAY INDICATE P. AERUGINOSA INFECTION

STUDY SHOWS THAT COVID-19 BOOSTER SHOT MAY HELP PROTECT SOME TRANSPLANT PATIENTS

CASES OF COVID-19 DELTA VARIANT ARE RISING IN THE US

TRIAL RESULTS SHOW NOVAVAX COVID-19 VACCINE CANDIDATE 90.4% EFFECTIVE

VACCINATION RATES AMONG LATINX AND AFRICAN AMERICAN COMMUNITIES LAG BEHIND

MODERNA APPLIES FOR FDA AUTHORIZATION FOR USE OF ITS COVID-19 VACCINE IN ADOLESCENTS

U.S. TO BUY 500M DOSES OF PFIZER-BIONTECH VACCINE FOR OTHER COUNTRIES

HEALTH CANADA APPROVES TRIKAFTA FOR CF PATIENTS AGES 12 AND UP

NEW STRATEGY CORRECTS CF SPLICING DEFECTS IN LAB MODELS

YOUNGER ADULTS’ COVID-19 VACCINATION RATES SLOWER THAN OLDER ADULTS

MANY LOW-INCOME IMMIGRANTS RESORT TO UNPROVEN COVID-19 TREATMENTS

SUPREME COURT REJECTS LATEST CHALLENGE TO AFFORDABLE CARE ACT

DELTA COVID-19 VARIANT SPREADING IN UNVACCINATED US COUNTIES, ANALYSIS FINDS

 

MAY, 2021

NEW CRISPR TECHNOLOGY OFFERS CONTROL OF EPIGENETIC INHERITANCE

SOCIAL DISTANCING INSIDE CAN PROVIDE A FALSE SENSE OF SECURITY

MANY WHO TEST POSITIVE FOR COVID-19 BUT DO NOT REQUIRE HOSPITAL CARE SEEK MEDICAL CARE IN FOLLOWING MONTHS

KB407 GENE THERAPY FOUND SAFE IN ANIMALS, IN-HUMAN TRIAL EXPECTED LATER THIS YEAR

CDC SAYS FULLY VACCINATED AMERICANS CAN NOW GO OUTSIDE WITHOUT A MASK

CPAP THERAPY MAY AFFECT BMI IN ADULTS WITH OSA, STUDY INDICATES

MANY PEOPLE STILL PREFER CONVENIENCE OF JOHNSON AND JOHNSON ONE-DOSE COVID-19 VACCINE

FDA PROMISES TO ISSUE NEW RULES WITHIN A YEAR BANNING MENTHOL IN TOBACCO PRODUCTS

REACHING ‘HERD IMMUNITY’ IS UNLIKELY IN THE U.S

CHILDREN ACCOUNT FOR 22.4% OF NEW #COVID19 CASES IN THE US

WORLD ORPHAN DRUG CONGRESS: RARE DISEASE TRIALS AND PATIENT REGISTRIES

FDA TO AUTHORIZE PFIZER-BIONTECH COVID-19 VACCINE FOR CHILDREN AGES 12 – 15

PDE4 INHIBITORS MAY HELP TREAT CF, DRY MOUTH

EU OPENS KAFTRIO TO ALL CF PATIENTS 12 AND UP WITH F508DEL MUTATION

ELOXX ADDS KALYDECO TO ONGOING PHASE 2 TRIAL OF ELX-02

OP-ED: ANTIBIOTIC RESISTANCE, CHRONIC DISEASE AND COVID-19 – A TRIPLE THREAT

CDC UPDATES GUIDELINES ON CORONAVIRUS, EMPHASIZING AIRBORNE TRANSMISSION

TOBRAMYCIN GIVEN IN NANOPARTICLES SHOWS POTENTIAL TO TREAT P. AERUGINOSA

MS1819 PLUS PERT IMPROVES DIGESTION IN PEOPLE WITH SEVERE EPI

SPLISENSE RAISES $28.5 MILLION TO ADVANCE RESTORATIVE CF THERAPY

SURVEY FINDS THAT MANY UNVACCINATED LATINX ADULTS IN THE US WANT COVID-19 SHOT

ANTIBODY COCKTAIL REDUCES HOSPITALIZATION, DEATH AMONG HIGH-RISK, NON-HOSPITALIZED PATIENTS WITH COVID-19

CDC SAYS FULLY VACCINATED CAN GO WITHOUT MASKS OR PHYSICAL DISTANCING IN MOST CIRCUMSTANCES

CDC SAYS MOST PEOPLE WHO ARE FULLY VACCINATED AGAINST COVID-19 AND HAVE NO SYMPTOMS DO NOT NEED TO BE TESTED FOR THE VIRUS, EVEN IF EXPOSED

SPIROMETRY MEASUREMENTS TAKEN AT HOME DON’T MATCH WITH THOSE OBTAINED IN CLINIC

EU, UK CONSIDER EXPANDING KAFTRIO TO CHILDREN AGES 6 AND OLDER

TWO STUDIES INDICATE COVID-19 MITIGATION MEASURES CAN HELP SCHOOLS STAY OPEN AND KEEP STUDENTS SAFE

US CHILDREN WITH CF HAVE BETTER LUNG FUNCTION THAN UK CHILDREN

HEALTH DISPARITY OBVIOUS IN AVAILABLE TREATMENTS FOR SICKLE CELL COMMUNITY

 

APRIL, 2021

SWEAT-MEASURING STICKER MAY AID CF DIAGNOSIS IN CHILDREN

LEAVING MIDDLE SEATS ON AIRPLANES VACANT MAY REDUCE RISK OF CORONAVIRUS EXPOSURE

RISK OF BRAIN BLOOD CLOTS IS HIGHER FROM COVID-19 INFECTION THAN FROM COVID-19 VACCINES

EXPERTS CONCERNED ABOUT IMPACT OF J&J CORONAVIRUS VACCINE PAUSE

FREE ONLINE CLASSES FOR THE CF COMMUNITY AT STROLO UNIVERSITY

CFRI JOINS 80 NATIONAL PATIENT GROUPS IN AN OPEN LETTER CALLING ON LAWMAKERS TO REJECT HEALTH POLICIES THAT DISCRIMINATE

OPTION 2 TRIAL TESTING MS1819 FOR EPI POSTS ‘MIXED’ TOPLINE RESULTS

RESPINOVA’S PULSEHALER DEVICE RECEIVES FDA APPROVAL

PHASE 2 TRIAL ADVANCING: BX004, PHAGE THERAPY FOR BACTERIAL INFECTIONS

RACIAL BIAS IN PULSE OXIMETRY MEASUREMENTS

APRIL 24TH IS TAKE BACK DAY – AN IMPORTANT REMINDER TO SAFELY DISPOSE OF UNUSED MEDICATION

CDC: HALF OF ALL US ADULTS HAVE RECEIVED AT LEAST ONE COVID-19 VACCINE DOSE

 

MARCH, 2021

 

FEBRUARY, 2021

OP-ED: SB 5020 INCLUDES GROUP KNOWN FOR DISCRIMINATORY PRACTICES

ASTRAZENECA VACCINE APPEARS TO SUBSTANTIALLY REDUCE TRANSMISSION OF THE CORONAVIRUS

FDA TO REVIEW TRIKAFTA FOR PATIENTS AS YOUNG AS SIX YEARS

KINNEAR PHARMACEUTICALS TO RECEIVE UP TO $3M TO FOR DEVELOPMENT OF ANTI-INFECTIVE FROM CF FOUNDATION

TRANSMISSION AND ANTIBIOTIC RESISTANCE OF ACHROMOBACHTER BACTERIA IN CYSTIC FIBROSIS

 

JANUARY, 2021

MS THERAPY BOOSTS TOBRAMYCIN’S EFFECTIVENESS AGAINST P. AERUGINOSA

AzurRx STARTS DOSING FIRST CF PATIENTS IN STUDY OF LIPASE ENZYME MS1819

MINORITIES IN US OFTEN INELIGIBLE FOR CFTR MODULATORS DUE TO POORLY STUDIED MUTATIONS

UPDATE: WASHINGTON STATE SENATE HEALTH AND LONG TERM CARE COMMITTEE HEARS TESTIMONY ON SB 5020: “Rx DRUG PRICE INCREASES”